2018-2019 AdooQ Catalog Book Available Click here to download

World Leading Inhibitor Supplier

United States
  • Toll Free 866-930-6790
Trusted by 10,000+ Scientists since 2006
  • Home /
  • Angiogenesis

Angiogenesis



Items 1 to 50 of 300 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction
Catalog No. Product Name Application Product Information
A11263

BMS-690514

VEGFR/EGFR Inhibitor
BMS-690514 is a potent and selective inhibitor of epidermal growth factor receptor (EGFR), HER2, and HER4, as well as the VEGF receptor kinases.
A12650

PKC 412 (Midostaurin)

PKC inhibitor
PKC 412 is a broad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms α/β/γ, PDFRβ, VEGFR2, Syk, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity.
A13718 SALE

Icotinib Hydrochloride

EGFR inhibitor
Icotinib hydrochloride is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).
A13681 SALE

AZD-9291 (Osimertinib)

EGFR inhibitor
AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.
A13588

Tyrphostin AG 183

EGFR inhibitor
Tyrphostin AG 183 inhibits EGFR (epidermal growth factor receptor) tyrosine kinase (IC50 = 800 nM).
A13755

CNX-2006

EGFR inhibitor
CNX-2006 is a potent, mutant-selective EGFR inhibitor with excellent in vitro activity in cells with activating EGFR mutations, as well as in cells harbouring the T790M mutation. CNX-2006 is the prototype for CO-1686, which is currently in a Phase I clinical trial for the treatment of EGFR-mutant lung cancer.
A13825

Icotinib

EGFR inhibitor
Icotinib is a potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR, EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).
A14985

Afatinib dimaleate

EGFR inhibitor
Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.
A15081

Erlotinib mesylate

EGFR inhibitor
Erlotinib mesylate is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM.
A15093

Gefitinib hydrochloride

EGFR Inhibitor
Gefitinib hydrochloride is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR.
A15272

Vandetanib trifluoroacetate

VEGFR/EGFR inhibitor
Vandetanib is a potent inhibitor of VEGFR2 with IC50 of 40 nM.
A15531

BIBX1382

EGFR inhibitor
BIBX1382 is a potent, selective inhibitor of EGFR tyrosine kinase (IC50 = 3 nM); displays > 1000-fold lower potency against ErbB2 (IC50 = 3.4 _mu_M) and a range of other related tyrosine kinases (IC50 > 10 _mu_M),
A15509

WHI-P180

EGFR/Cdk2 inhibitor
WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
A15516

AZ5104

EGFR inhibitor
AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of <1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1.
A15551

AZD3759

EGFR inhibitor
AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR). It binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR.
A14408

ASP8273 (Naquotinib)

irreversible EGFR inhibitor
ASP8273 is an orally available, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity.
A14416

EGF816 (Nazartinib)

EGFR T790M inhibitor
EGF816 is a novel covalent inhibitor of mutant-selective EGFR; overcomes T790M-mediated resistance in NSCLC.
A15940

AG-18 (Tyrphostin 23)

EGFR Inhibitor
AG-18 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 35 ,M in the human epidermoid carcinoma cell line A431.
A15955

DM1-SMCC

potent EGFR inhibitor
DM1-SMCC is DM1 with a reactive linker SMCC, which can react with antibody to make antibody drug conjugate.
A10005 SALE

(-)-Epigallocatechin gallate

Antioxidant, antiangiogenic, antitumor agent
(-)-Epigallocatechin gallate is a potent anti-oxidant polyphenol flavonoid isolated from green tea.
A10706 SALE

Pelitinib (EKB-569)

EGFR inhibitor
Pelitinib (EKB-569) is a 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity.
A10638 SALE

Neratinib (HKI-272)

HER2 inhibitor
Neratinib (HKI-272) is a tyrosine kinase inhibitor.
A10211 SALE

Canertinib (CI-1033)

HER2/ErbB2 inhibitor
Canertinib (CI-1033) is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC50 0.8 nM), HER-2 (IC50 19 nM) and ErbB-4 (IC50 7 nM).
A10141 SALE

BIBW2992 (Afatinib)

EGFR inhibitor
BIBW2992 (Afatinib) is tyrosine kinase inhibitor (TKI) that irreversibly inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases.
A10116 SALE

AZD8931 (Sapitinib)

pan-EGFR/pan-erbB inhibitor
AZD8931 is an oral, equipotent inhibitor of ErbB1, ErbB2 and ErbB3 receptor signaling.
A10991

WZ4002

EGFR Inhibitor
WZ4002 is EGFR inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) which is detected in 50% of clinically resistant patients to gefitinib or erlotinib.
A10422 SALE

Gefitinib (Iressa)

EGFR Inhibitor
Gefitinib is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells.
A10362 SALE

Erlotinib HCl

EGFR inhibitor
Erlotinib hydrochloride is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).
A10514 SALE

Lapatinib Ditosylate

HER2 inhibitor
Lapatinib is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway.
A11022 SALE

AG-1478 (Tyrphostin AG-1478)

EGFR Inhibitor
AG-1478 (Tyrphostin AG-1478) is an inhibitor of EGFR kinase with an IC50 value of 3 nM.
A10678 SALE

OSI-420

EGFR Inhibitor
OSI-420 (Desmethyl Erlotinib,CP-473420) is an orally active EGFR tyrosin kinase inhibitor, which inhibits receptor tyrosine kinases (TKs) by inhibition of the intercellular domain .
A10246 SALE

CUDC-101

HDAC inhibitor
CUDC-101 is a novel compound which inhibits multiple targets, which is designed to inhibit HDAC, EGFR and Her2.
A10992

WZ8040

EGFR Inhibitor
WZ8040 is a novel EGFR inhibitors that suppress the growth of EGFR-T790M-containing cell lines and inhibit EGFR phosphorylation.
A10990

WZ3146

EGFR Inhibitor
WZ3146 is an inhibitor of EGFR receptor kinase mutants carrying a mutation in an active site gatekeeper residue (T790M) and is much less potent against wild-type EGFR kinase.
A10702

PD153035 (HCl salt)

EGFR inhibitor
PD153035 is an extremely potent and specific inhibitor of the tyrosine kinase activity of EGFR.
A10242 SALE

CP-724714

HER2/ErbB2 inhibitor
CP-724714 is an orally available, small molecule, potent HER-2 tyrosine kinase inhibitor that inhibits HER2 kinase (IC50 3.8 ng/ml) .
A11209 SALE

BMS 599626 (AC480)

EGFR Inhibitor
BMS 599626 is an orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases (IC50=22, 32 and 190 nM, respectively) with potential antineoplastic activity.
A11027

Arry-380 analog

HER2 Inhibitor
ARRY-380 is an ErbB-2 inhibitor that selectively binds to and inhibits the phosphorylation of ErbB-2, resulting in growth inhibition and death of ErbB-2-expressing tumor cells.
A11028

AV-412

EGFR inhibitor
AV-412 is an EGFR/HER2 inhibitor that binds to and inhibits the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2), which may result in the inhibition of tumor growth and angiogenesis.
A10047 SALE

AG-490

EGFR inhibitor
AG 490 is a selective inhibitor of EGF receptor tyrosine kinase (IC50 values are 2 and 13.5 μM for EGFR and ErbB2 respectively). Also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
A10043 SALE

AEE788

EGFR inhibitor
AEE788 is an orally bioavailable multiple-receptor tyrosine kinase inhibitor that inhibits phosphorylation of the tyrosine kinases of EGFR, HER2 and VEGF2.
A10210 SALE

Chrysophanic acid (Chrysophanol)

EGFR inhibitor
Chrysophanic acid (Chrysophanol) blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway.
A11051 SALE

PF299804 (Dacomitinib, PF299)

EGFR inhibitor
PF299804 is a potent, orally available, irreversible inhibitor of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HER2, and HER4.
A11057

XL647 (Tesevatinib)

GFR, HER2 and VEGFR inhibitor
XL647 is an orally bioavailable small-molecule RTK inhibitor that binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including EGFR, HER2, ERBB2, VEGFR and EphB4.
A11155 SALE

AST-1306

EGFR Inhibitor
AST-1306, a novel anilino-quinazoline compound, inhibits the enzymatic activities of wild-type epidermal growth factor receptor (EGFR) and ErbB2 as well as EGFR resistant mutant in both cell-free and cell-based systems.
A10286 SALE

Daphnetin

EGFR, PKA,PKC inhibitor
Daphnetin is a coumarin analog that acts as an inhibitor of several protein kinases. It inhibits EGFR kinase (IC50 = 7.67 µM), PKA (IC50 = 9.33 µM), and PKC (IC50 = 25 µM), in vitro. The inhibition of EGFR kinase by daphnetin was competitive to ATP and non-competitive to the peptide substrate. Also acts as a potent antioxidant and anti-malarial agent.
A10612 SALE

Mubritinib (TAK 165)

HER2/ErbB2 inhibitor
Mubritinib (TAK 165) is a potent EGFR and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 µM, respectively. Mubritinib(TAK 165) also inhibits p33cdk2 and p33cdk5.
A11158

ARRY334543 (Varlitinib)

EGFR inhibitor
ARRY334543 is a potent, orally active small molecule inhibitor of EGFR and ErbB-2.
A10426 SALE

Genistin (Genistoside)

-
Genistin is an isoflavone found in a number of dietary plants like soy and kudzu. It was shown to stimulate estrogen-dependent breast cancer cell growth in vivo.
A11236

TAK-285

HER2/EGFR inhibitor
TAK-285 is an investigational HER2/EGFR inhibitor that penetrates the CNS in Rats with an Intact Blood Brain Barrier (BBB). TAK-285 has inhibitory activity against HER2 and EGFR kinases with IC50 values for HER2 and EGFR of 17 nmol/L (95% CI 12-24) and 23 nmol/L (95% CI 18-30), respectively.[1]

Items 1 to 50 of 300 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction
FILTER BY:

Shopping Options

Category
  1. EGFR / HER2 (76)
  2. FGFR (32)
  3. PDGFR (39)
  4. VEGFR (78)
  5. VDA (4)
  6. HIF (19)
  7. FLT3 (29)
  8. ALK (19)
  9. BTK (15)
  10. FAK (11)
  11. Syk (13)
  12. Bcr-Abl (31)
Target
  1. Abl (6)
  2. ALK (1)
  3. Aurora A (8)
  4. Aurora B (4)
  5. Aurora C (1)
  6. Axl (1)
  7. B-Raf (3)
  8. Bcr-Abl (1)
  9. C-Raf (Raf-1) (3)
  10. CDK (1)
  11. CDK2 (2)
  12. CDK4 (1)
  13. Chk2 (1)
  14. CSF1R (5)
  15. DNMT (1)
  16. EGFR (24)
  17. EGFR Exon 19 Deletion (1)
  18. EGFR L858R (5)
  19. EGFR L861Q (2)
  20. EGFR T790M (9)
  21. EGFR wild type (2)
  22. EphB4 (2)
  23. ErbB2 (3)
  24. ErbB3 (1)
  25. ErbB4 (2)
  26. FAK (10)
  27. FGFR (2)
  28. FGFR1 (23)
  29. FGFR2 (11)
  30. FGFR3 (12)
  31. FGFR4 (9)
  32. FLT3 (24)
  33. HDAC (1)
  34. HER2 (2)
  35. IGF1R (1)
  36. JAK2 (7)
  37. JAK3 (2)
  38. Kit (14)
  39. Lck (1)
  40. Lyn (1)
  41. Mer (1)
  42. PDGFR (1)
  43. PDGFRα (9)
  44. PDGFRβ (17)
  45. PKCα (1)
  46. PKCβ (1)
  47. PYK2 (4)
  48. RET (6)
  49. Src (5)
  50. STAT1 (1)
  51. Syk (1)
  52. TrkA (2)
  53. VEGFR1 (FLT1) (12)
  54. VEGFR2 (FLK1) (25)
  55. VEGFR3 (FLT4) (11)
Actions
  1. Activator (2)
  2. Antagonist (2)
  3. Inhibitor (279)

Adooq Guarantee

Guaranteed product quality

We promise all products perform as described.

New Catalog Book

Receive our newsletter

To keep up to date with the latest products, news from us. We only send a few emails a year and you can unsubscribe at any time.

We Using Safe Payments:
© 2006-2018 AdooQ BioScience. All Rights Reserved.